Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report

BACKGROUND: Pancreatic mucinous cystadenocarcinoma (MCAC) is a rare malignancy with a poor prognosis when it presents metastases at diagnosis. Due to its very low incidence, there are no clear recommendations for the treatment of advanced disease. Olaparib (an oral PARP inhibitor) has been approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Marco, Mariacristina, Carloni, Riccardo, De Lorenzo, Stefania, Mosconi, Cristina, Palloni, Andrea, Grassi, Elisa, Filippini, Daria Maria, Ricci, Angela Dalia, Rizzo, Alessandro, Di Federico, Alessandro, Santini, Donatella, Turchetti, Daniela, Ricci, Claudio, Ingaldi, Carlo, Alberici, Laura, Minni, Francesco, Golfieri, Rita, Brandi, Giovanni, Casadei, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739147/
https://www.ncbi.nlm.nih.gov/pubmed/33362915
http://dx.doi.org/10.4251/wjgo.v12.i12.1456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739147/
https://www.ncbi.nlm.nih.gov/pubmed/33362915
http://dx.doi.org/10.4251/wjgo.v12.i12.1456

Ejemplares similares